Hepatitis B is still the main cause of chronic liver disease in China, causing a huge burden on people’s health and economic development. During the past two decades, great efforts in the prevention and treatment of hepatitis B have been made, with a lot of achievements. However, antiviral therapy for hepatitis B virus (HBV) infection and disease eradication remain a major challenge. This paper focuses on the prevalence of HBV infection and its prevention and treatment in China.
To cite this article
Current epidemiology, prevention and treatment of Hepatitis B in China
Infectious Diseases & Tropical Medicine 2017; 3 (3): e412
Submission date: 12 Sep 2017
Revised on: 15 Sep 2017
Accepted on: 22 Sep 2017
Published online: 02 Oct 2017
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.